GILD Gilead Sciences, Inc.
GILD Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 2 scans as of 2026-08-14 2 bull converging
POC $121.73 · VWAP $127.46 · +9.0% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
4 watchlists
GILD Price Structure
Loading timeframes…
Peers
Every watchlist GILD belongs to, members best 30-day change first — GILD highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@healthcare-scan
@healthcare
@ibb
@biotech-scan
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-03-31: revenue $6.96B, net income $2.02B (SEC filing). Across the print the stock moved -3.6% (close before → first close after).
full note →Against street estimates
How GILD's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about GILD from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Aug 4
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance
GILD research tape
97 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.